Will Merck's Failure With Tredaptive Impact How Drugs Are Approved in Europe?
Just before the holiday season, Merck announced that it was halting a major clinical trial with its cardiovascular (CV) disease drug, Tredaptive. Tredaptive is a drug which combines extended-release niacin with laropiprant. Niacin (also known as Vitamin B3) is a drug that has been used for decades to help patients control dyslipidemia. Basically, niacin is one of the few compounds known to raise HDL, the so-called good cholesterol, albeit modestly. It has been prescribed to patients at risk for heart disease with abnormally low HDL. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 2, 2013 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Vitamin pill that may slow Alzheimer's goes on trial
• Tests offer hope to UK's 417,000 sufferers • Delaying disease could save 30,000 lives a yearA vitamin pill that could slow the progression of Alzheimer's disease is to enter human trials after scientists found it protected animals from memory loss associated with the condition.High doses of vitamin B3 will be given to 70 people who have recently been diagnosed with the disease as part of the trial due to begin in the new year, which is open to volunteers over the age of 50.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 5, 2008 Category: Science Authors: Ian Sample, science correspondent Tags: Neuroscience Medical research Health Society Nutrition Life and style Dementia Alzheimer's Memory Source Type: news
